Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $75.55 is 165.09% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 75.71||$ 80|
|Low:||$ 71||$ 28.50|
ETFs with MRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.78%||Invesco DWA Healthcare Momentum ETF (PTH)||+13.65 (21.01%)|
|2.8%||Invesco DWA NASDAQ Momentum ETF (DWAQ)||+18.82 (19.87%)|
|1.52%||Invesco DWA SmallCap Momentum ETF (DWAS)||+10.80 (26.95%)|
|0.4%||iShares Microcap ETF (IWC)||+14.60 (18.77%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Our precision oncology clinical programs utilize genomic testing to identify and select cancer patients who we believe would be most likely to benefit from targeted treatment. In immuno-oncology, we are advancing a clinical program where our product candidate has the potential to improve the immune environment of tumor cells and enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. Our KRAS inhibitor program is focused on developing novel inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. We also have additional preclinical programs which include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. ... More ...
Nasdaq Official Price
May 21, 2019
May 20, 2019